Orion Oyj Class A · OMXHEX:ORNAV
Orion Oyj Class A — Orion Corp New B Shs — Q3 2025 Earnings Presentation
16 slides from Orion Oyj Class A's earnings presentation, Oct 29, 2025
Slide 1: Orion Interim Report January-September 2025
Orion Interim Report January-September 2025 28 October 2025
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of
Slide 3: Q3 2025 Highlights
Q3 2025 Highlights • European Commisson approval for darolutamide + ADT in patients with mHSPC • All-time-high Nubeqa® royalties and product deliveries to Bayer in Q3 • Generics and Consumer Health had a strong quarter • ODM-105 (tasipimidine) Phase 2 trial did not reach its target • Development for
Slide 4: Q3 2025 Financial highlights
Q3 2025 Financial highlights Net sales, EUR million Operating profit, EUR million Operating cash flow per share, EUR Operating profit margin 28.6% (42.9%) -10.2% -40.1% +15.3% 471.3 202.0 0.55 423.2 0.48 130.0 130.0 121.0 +24.0% 341.3 +68.1% 72.0 Q3/2024 Q3/2025 Q3/2024 Q3/2025 Q3/2024 Q3/2025 4 28
Slide 5: Net sales bridge (MEUR) from Q3/24 to Q3/25
Net sales bridge (MEUR) from Q3/24 to Q3/25 471.3 The decline is due to major milestones total of EUR 130 million booked in Q3/2024 (vs. no major milestones in Q3/2025). Underlying net sales increased by EUR 70.9 million. 6.9 2.1 0.8 423.2 2.1 -0.9 -59.1 Q3/2024 1 2 3 4 5 6 Q3/2025 1 Innovative Medi
Slide 6: Operating profit bridge (MEUR) Q3/24 to Q3/25
Operating profit bridge (MEUR) Q3/24 to Q3/25 49.8 3.7 The decline is due to major milestones total 16.0 of EUR 130 million booked in Q3/2024 (vs. 202.0 no major milestones in Q3/2025). -4.6 121.0 -129.9 -3.9 -11.8 Q3/2024 1 2 3 4 5 6 7 Q3/2025 1 Change in sales volume 5 Milestones 2 Changes in pric
Slide 7: January-September 2025 Financial highlights
January-September 2025 Financial highlights Net sales, EUR million Operating profit, EUR million Operating cash flow per share, EUR Operating profit margin 25.4% (29.2%) +7.8% -6.3% +14.5% 1,194.2 323.8 1.67 1,108.0 303.5 1.46 130.0 130.0 +22.1% +56.6% 978.0 193.8 YTD9/2024 YTD9/2025 YTD9/2024 YTD9/
Slide 8: Innovative Medicines
Innovative Medicines -25.7% +13.0% Nubeqa® sales (MEUR) 230.2 415.6 166 18.4 152 367.8 140 48 171.1 36 130.0 5.5 130.0 44 95 92 21.5 397.2 72 26 5.1 62 38 165.6 50 21 116 118 22 96 +70.7% 216.3 +74.8% 18 95.2 69 MEUR MEUR 51 54 41 32 Q3/2024 Q3/2025 YTD9/2024 YTD9/2025 2023 2024 2024 2024 2024 2025
Slide 9: Branded Products
Branded Products +3.1% +8.8% • Growth slowed down somewhat 66.7 68.7 226.1 in Q3 due to timing of some 5.9 6.8 207.9 21.8 deliveries 17.8 • CNS YTD sales growing mainly 21.0 19.8 71.4 due to entacapone sales in Japan 67.4 • Easyhaler® budesonide- formoterol the growth driver for respiratory therapy
Slide 10: Generics and Consumer Health
Generics and Consumer Health 5.4% 4.2% • New launches and good 135.9 402.5 availability of Orion products in 128.9 386.2 Finland supported growth 33.9 98.3 32.1 96.5 • Good availability of Orion products in Scandinavia supported growth • Very good performance in Q3 and YTD taking into account that 9
Slide 11: Animal Health
Animal Health +6.8% +13.2% • The growth came from various 33.5 105.5 different products and regions 31.3 93.2 6.2 25.4 • In Q3 the growth was somewhat 7.0 25.8 slowed down by the timing of some deliveries 27.3 80.1 24.4 67.4 MEUR MEUR Q3/2024 Q3/2025 YTD9/2024 YTD9/2025 Other products Sedatives prod
Slide 12: TOP products and net sales split in YTD9/2025
TOP 10 products and net sales split in YTD9/2025 EUR vs. Product or product portfolio million YTD9/2024 1. Nubeqa® 397.2 +83.6% 4% 9% 2. Easyhaler® product portfolio 129.7 +7.9% 3. Entacapone products1 64.5 +4.6% 35% 4. Dexdomitor®, Domitor®, Domosedan®, Antisedan® 25.4 -1.6% 5. Divina® series 21.8
Slide 13: Orion's key clinical development pipeline
Orion’s key clinical development pipeline Developed by Trial/compound Indication (or modality for pre-clinical assets) Phase I Phase II Phase III Registration ARASTEP (darolutamide) BCR (prostate cancer) DASL-HiCaP (darolutamide) (Neo-)Adjuvant prostate cancer OMAHA-003 (opevesostat) (later-line) me
Slide 14: Progress toward decarbonization targets
Progress toward decarbonization targets Q3 Turku steam project: Construction progressing to electrify steam production, expected to be operational in Q1 2026 70% Orion commits to reduce absolute Scope Oulu plant: Successfully completed ahead of schedule transition scope 1 and 2 greenhouse gas (GHG)
Slide 15: Outlook for 2025
Outlook for 2025 (specified on 28 Oct 2025) Net sales EUR 1,640–1,720 million Operating profit EUR 410–490 million 15 28 October 2025 © Orion Corporation
Slide 16: Upcoming events
Upcoming events Financial Statement Release for 2025 12/2/2026 AGM planned to be held 24/3/2026 Interim Report 1–3/2026 23/4/2026 Half-Year Financial Report 1–6/2026 17/7/2026 Interim Report 1–9/2026 28/10/2026 The Financial Statements and the Report by the Board of Directors for 2025 will be publis